logo

For the Inventor, By the Inventor

Barcelona, Spain

Minoryx Therapeutics S.l.

Calculating rank
USPTO Granted Patents = 10


Forward Citations = 17

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Ana Maria García Collazo (6 out of 6 patents)

silverMedal Marc Martinell Pedemonte (6 out of 19 patents)

bronzeMedal Maria Pilar Pizcueta Lalanza (5 out of 6 patents)

4.  Xavier Barril Alonso (3 out of 4 patents)

5.  Elena Cubero Jordà (3 out of 3 patents)

6.  Marc Revés Vilaplana (2 out of 2 patents)

7.  Richard Spurring Roberts (2 out of 4 patents)

8.  Johannes B M Rewinkel (2 out of 2 patents)

9.  Sander De Wilde (2 out of 4 patents)

10.  Wolter Ten Hoeve (2 out of 26 patents)

11.  Johannes Nicolaas Koek (2 out of 5 patents)

12.  David John Augustus Eckland (2 out of 2 patents)

13.  Laura Pilar Rodríguez Pascau (2 out of 2 patents)

14.  Ana María García Collazo (1 out of 1 patent)

15.  Guillem Pina Laguna (1 out of 1 patent)


10 patents:

1. 12673048 - Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione (2026-07-07),
2. 11957670 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases (2024-04-16),
3. 11938122 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease (2024-03-26),
4. 11739072 - Heteroaryl compounds and their use (2023-08-29),
5. 11731963 - Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof (2023-08-22),
6. 11440898 - Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase (2022-09-13),
7. 11174242 - Heteroaryl compounds and their use (2021-11-16),
8. 11124505 - Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof (2021-09-21),
9. 10179126 - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders (2019-01-15),
10. 9782395 - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders (2017-10-10),
Company Overview
Minoryx Therapeutics S.L. is a biopharmaceutical company based in Barcelona, Spain, focused on developing innovative therapies for rare genetic diseases. The company specializes in advancing treatments for conditions related to lysosomal storage disorders, leveraging its expertise in drug development and precision medicine. Minoryx aims to address unmet medical needs through its proprietary technologies and collaborative research efforts, contributing to the advancement of healthcare solutions for patients with limited treatment options.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

10 Patents

#72 in Barcelona

#219 in Spain

#56,119 in the World

Barcelona, ES
Barcelona, Spain

Minoryx Therapeutics S.l.

Forward Citations = 17

17 inventors:

goldMedal Ana Maria García Collazo (6 out of 6 patents)

silverMedal Marc Martinell Pedemonte (6 out of 19 patents)

bronzeMedal Maria Pilar Pizcueta Lalanza (5 out of 6 patents)

4.  Xavier Barril Alonso (3 out of 4 patents)

5.  Elena Cubero Jordà (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Minoryx Therapeutics S.l.. Retrieved from https://idiyas.com/company/minoryx-therapeutics-s-l

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…